Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Deffered Revenue (2017 - 2018)

Historic Non-Current Deffered Revenue for Puma Biotechnology (PBYI) over the last 2 years, with Q4 2018 value amounting to $5.8 million.

  • Puma Biotechnology's Non-Current Deffered Revenue rose 756.57% to $5.8 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.8 million, marking a year-over-year increase of 756.57%. This contributed to the annual value of $5.8 million for FY2018, which is 756.57% up from last year.
  • Latest data reveals that Puma Biotechnology reported Non-Current Deffered Revenue of $5.8 million as of Q4 2018, which was up 756.57% from $5.9 million recorded in Q3 2018.
  • In the past 5 years, Puma Biotechnology's Non-Current Deffered Revenue ranged from a high of $5.9 million in Q3 2018 and a low of $5.4 million during Q4 2017